Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola Post published:February 10, 2026 Post category:Interviews/Pα+
Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation Post published:February 5, 2026 Post category:Analysis/Interviews/News
āChanges Are Never Linearā: Joost Breeksema on the Human Side of Psychedelic Therapy Post published:January 27, 2026 Post category:Interviews
Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next Post published:December 10, 2025 Post category:Interviews/Pα+
Bringing Psilocybin to Market: Compassā Steve Levine on Infrastructure, Access and Competition Post published:November 26, 2025 Post category:Interviews/Pα+
Beyond the Brain Reset: Ćscar Soto on Mechanisms of Psychedelic Action Post published:November 13, 2025 Post category:Interviews
A European Model: Robert Schoevers on the Continentās Growing Psychedelic Research Agenda Post published:October 22, 2025 Post category:Interviews
Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall Post published:October 14, 2025 Post category:Interviews/Pα+
āNo Prejudice, No Hypeā: Florence Butlen-Ducuing on Europeās Psychedelic Renaissance Post published:September 11, 2025 Post category:Interviews/Pα+
From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research Post published:August 12, 2025 Post category:Analysis/Interviews